Major U.S. Obesity Societies Issue New Evidence-Based Guidance on Weight Loss Medications | Research

The takeaway

TOS, OMA, and OAC jointly released updated pharmacological management guidance for obesity using the GRADE framework, addressing barriers to treatment access.

40%+ of U.S. adults
Obesity prevalence continues rising with severe obesity increasing fastest

What the researchers found

Joint expert guidance from three major U.S. obesity organizations provides updated, evidence-graded recommendations for pharmacological obesity management.

Why it matters

Despite effective medications being available, obesity remains undertreated due to stigma, lack of insurance coverage, and limited clinician training. Updated guidance from leading societies can help standardize care.

How the study worked

Expert guidance statement using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to systematically evaluate evidence for obesity medications.

What this study cannot tell us

Guidance statement rather than systematic review; GRADE assessments depend on available trial data which may not capture long-term outcomes.

How to read the evidence

Expert guidance using GRADE framework — systematic evaluation of evidence quality, but recommendations reflect expert interpretation of available data.

When this study was published

Published 2026 in Obesity. Reflects the most current FDA-approved obesity pharmacotherapies.

The bigger picture

This guidance represents a shift toward treating obesity as a chronic disease deserving the same evidence-based pharmacological approach as diabetes or hypertension.

Questions still open

Will this guidance influence insurance coverage policies for obesity medications?
How will these recommendations be implemented in primary care settings with limited obesity medicine training?

Common questions

What is the GRADE approach?

GRADE is a systematic framework used to evaluate the quality of evidence and strength of recommendations in clinical guidelines, helping ensure guidance is based on the best available science.

Why is obesity still undertreated if medications exist?

Barriers include limited insurance coverage, weight stigma, insufficient clinician training in obesity medicine, and socioeconomic disparities in healthcare access.

Read the original research

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.

Obesity (Silver Spring, Md.)

View on PubMed ↗Publisher’s paper ↗

Citation

Alexander, Lydia; Purnell, Jonathan Q; Burridge, Karlijn; Cornier, Marc-André; Golden, Angela; Bade, Deborah; Look, Michelle; Nadglowski, Joe; Ávila-Oliver, Camila; Novillo, Francisco; Rojas-Gómez, Ana María; Hussey, Brad; Salas, Ximena Ramos. (2026). Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.. Obesity (Silver Spring, Md.). https://doi.org/10.1002/oby.70164